Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Trials & Tribulations Protecting the cure: Why the future of radiation oncology must be precision-guided April 10, 2026Vol.52 No.14By J. Isabelle Choi
FreeTrials & Tribulations Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients March 27, 2026Vol.52 No.12By W. Kimryn Rathmell
Colorectal cancer is now the leading cause of cancer death in patients under 50Why aren’t 45-year-olds getting their recommended CRC screenings? March 27, 2026Vol.52 No.12By Sara Willa Ernst
Trials & Tribulations Why infection and immunity matter for Florida’s cancer patients February 13, 2026Vol.52 No.06By Eduardo Sotomayor
FreeTrials & Tribulations Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore January 30, 2026Vol.52 No.04By Les Biller
Premarin’s 84-year hold on the market ends as FDA approves a generic versionTrade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer January 23, 2026Vol.52 No.03By Claire Marie Porter
News Analysis ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook January 16, 2026Vol.52 No.02By Jacquelyn Cobb and Paul Goldberg
Health Equity New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years January 16, 2026Vol.52 No.02By Sara Willa Ernst
Trials & Tribulations A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers January 16, 2026Vol.52 No.02By Kevin King
